Vaishali Thakkar
Research Subjects
Vaishali Thakkar has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Tejal Gandhi
Department of Pharmaceutics, Anand Pharmacy College, Anand, India
16 shared publications - Purvi Shah
Parul Institute of Pharmacy and Research, Parul University
10 shared publications - Hardik Rana
Department of Pharmaceutics, Anand Pharmacy College, Anand, India
9 shared publications - Saloni Dalwadi
Gujarat Technological University
8 shared publications - Kalpana Patel
Department of Pharmaceutical Quality Assurance, Anand Pharmacy College, Anand, India
7 shared publications Mukesh Gohel
Department of Pharmaceutics, Anand Pharmacy College, Anand-388 001, Gujarat, India
7 shared publications
Latest Publications
- 27 October 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (8) , 340
NanoMiLens (Nano-Micelle Loaded Hydrogel Contact Lenses) of Tofacitinib Citrate: Amalgamation, Development, Optimization and Characterization
- 27 October 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (8) , 340
NanoMiLens (Nano-Micelle Loaded Hydrogel Contact Lenses) of Tofacitinib Citrate: Amalgamation, Development, Optimization and Characterization
- Open Access
- 26 October 2026
- Published by Springer Nature in Bulletin of the National Research Centre
- Vol. 50 (1) , 129
Pediatric-friendly Smart Oro-solid Carbamazepine Dry Suspension (SOS-CDS): optimization, functionality and in-vivo taste determination
Background: Pediatric formulations are challenging to design due to considerations of convenience. Many children are suffering from an epileptic condition at an early age. Continuing anti-epileptic treatment can influence bone metabolism in children. The research was undertaken to design a pediatric and industry approachable smart stable dosage form of carbamazepine (CBZ) supplemented with Vitamin D (Vit D). Methods: Smart Oro-solid Carbamazepine Dry Suspension (SOS-CDS) was formulated using a liquorice-based suspending agent. DSC and FTIR were performed to observe interactions among CBZ, Vit D, and other excipients. Screening of various variables was performed using Failure Mode and Effects Analysis (FMEA), and the results were further optimized using a Central Composite Design (CCD) with two independent variables (suspending agent and mixing speed) and three dependent variables (sedimentation volume, blend uniformity, and %CDR). The designed SOS-CDS was evaluated for its stability and other physicochemical parameters. BATA model was utilized to assess the taste masking of carbamazepine. Results: DSC and FTIR spectra showed no interaction between the drug and excipients. QbD approach successfully optimized the SOS-CDS, identifying suspending agent concentration and mixing speed as critical variables. A total of 13 experiments were designed and evaluated. Optimized SOS-CDS showed good micromeritics properties and a desired sedimentation volume, with 93.7% release at 420 min. BATA model revealed the taste masking of CBZ. Conclusion: The major concern with the current formulation was its instability in the presence of light and moisture. The developed SOS-CDS was stable due to its intelligent mechanism. In addition, long-term use of CBZ causes bone degeneration, which may be overcome by supplementing Vitamin D. Liquorice was explored as a masking agent for the bitter taste of CBZ and was confirmed in the BATA model. The newer SOS-CDS was stable and had controlled release. The developed formulation will be useful at an industrial scale.
- 26 October 2026
- Published by Springer Nature in Bulletin of the National Research Centre
- Vol. 50 (1) , 129
Open AccessPediatric-friendly Smart Oro-solid Carbamazepine Dry Suspension (SOS-CDS): optimization, functionality and in-vivo taste determination
Background: Pediatric formulations are challenging to design due to considerations of convenience. Many children are suffering from an epileptic condition at an early age. Continuing anti-epileptic treatment can influence bone metabolism in children. The research was undertaken to design a pediatric and industry approachable smart stable dosage form of carbamazepine (CBZ) supplemented with Vitamin D (Vit D). Methods: Smart Oro-solid Carbamazepine Dry Suspension (SOS-CDS) was formulated using a liquorice-based suspending agent. DSC and FTIR were performed to observe interactions among CBZ, Vit D, and other excipients. Screening of various variables was performed using Failure Mode and Effects Analysis (FMEA), and the results were further optimized using a Central Composite Design (CCD) with two independent variables (suspending agent and mixing speed) and three dependent variables (sedimentation volume, blend uniformity, and %CDR). The designed SOS-CDS was evaluated for its stability and other physicochemical parameters. BATA model was utilized to assess the taste masking of carbamazepine. Results: DSC and FTIR spectra showed no interaction between the drug and excipients. QbD approach successfully optimized the SOS-CDS, identifying suspending agent concentration and mixing speed as critical variables. A total of 13 experiments were designed and evaluated. Optimized SOS-CDS showed good micromeritics properties and a desired sedimentation volume, with 93.7% release at 420 min. BATA model revealed the taste masking of CBZ. Conclusion: The major concern with the current formulation was its instability in the presence of light and moisture. The developed SOS-CDS was stable due to its intelligent mechanism. In addition, long-term use of CBZ causes bone degeneration, which may be overcome by supplementing Vitamin D. Liquorice was explored as a masking agent for the bitter taste of CBZ and was confirmed in the BATA model. The newer SOS-CDS was stable and had controlled release. The developed formulation will be useful at an industrial scale.
- 22 October 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (8) , 330
Decoding Formulation Complexity: Comparative Performance of Statistical, Machine Learning, and Artificial Intelligence Models in Intelligent Nano Depot (iNDEP) Design
Artificial intelligence (AI) and machine learning (ML) are increasingly explored to improve predictive modelling and optimization in pharmaceutical formula
- 22 October 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (8) , 330
Decoding Formulation Complexity: Comparative Performance of Statistical, Machine Learning, and Artificial Intelligence Models in Intelligent Nano Depot (iNDEP) Design
Artificial intelligence (AI) and machine learning (ML) are increasingly explored to improve predictive modelling and optimization in pharmaceutical formula
- 4 August 2026
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 40 (1) , 195
Comparative analysis of supervised machine learning algorithms for transdermal drug delivery in brain disorders
- 4 August 2026
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 40 (1) , 195
Comparative analysis of supervised machine learning algorithms for transdermal drug delivery in brain disorders
- 2 May 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (10) , 1-13
Ufasome-based transdermal dual-vesicular gel of febuxostat and aceclofenac for sustained gout therapy: formulation optimization and pharmacodynamic evaluation
Gout is a prevalent inflammatory arthritic disorder affecting more than 40 million people worldwide, with incidence increasing due to aging populations, lifestyle factors, and metabolic comorbidities. Febuxostat (FEB), a xanthine oxidase inhibitor used for urate-lowering therapy, often triggers acute gout flares during treatment initiation, necessitating concurrent anti-inflammatory therapy such as aceclofenac (ACE). However, the oral administration of both drugs is associated with poor aqueous solubility, first-pass metabolism, and gastrointestinal adverse effects. The present study aimed to develop and optimize a ufasome-based transdermal gel co-loaded with FEB and ACE to provide controlled and sustained drug release for improved gout management. Ufasomes were prepared using the thin-film hydration method and optimized through a Box–Behnken design. The optimized formulation exhibited nanosized vesicles (199 nm for FEB and 365 nm for ACE), high entrapment efficiency (> 80%), and stable zeta potential values. The ufasomal gel demonstrated sustained in vitro drug release over 24 h compared with plain drug gel, while ex vivo permeation studies indicated controlled diffusion across rat skin, suggesting formation of a drug reservoir within cutaneous layers. The drug release follows 1st order model for FEB and ACE. In vivo pharmacodynamic studies showed significant reductions in serum uric acid levels (p < 0.01) and paw edema volume (p < 0.001). These findings suggest that the FEB–ACE ufasomal transdermal gel offers a sustained delivery platform that may improve therapeutic outcomes and patient compliance in gout therapy. The novelty of this work lies in the dual-drug ufasomal transdermal system integrating urate-lowering and anti-inflammatory therapy in a single formulation, offering a potential alternative to conventional oral treatment for gout management with improved therapeutic convenience.
- 2 May 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (10) , 1-13
Ufasome-based transdermal dual-vesicular gel of febuxostat and aceclofenac for sustained gout therapy: formulation optimization and pharmacodynamic evaluation
Gout is a prevalent inflammatory arthritic disorder affecting more than 40 million people worldwide, with incidence increasing due to aging populations, lifestyle factors, and metabolic comorbidities. Febuxostat (FEB), a xanthine oxidase inhibitor used for urate-lowering therapy, often triggers acute gout flares during treatment initiation, necessitating concurrent anti-inflammatory therapy such as aceclofenac (ACE). However, the oral administration of both drugs is associated with poor aqueous solubility, first-pass metabolism, and gastrointestinal adverse effects. The present study aimed to develop and optimize a ufasome-based transdermal gel co-loaded with FEB and ACE to provide controlled and sustained drug release for improved gout management. Ufasomes were prepared using the thin-film hydration method and optimized through a Box–Behnken design. The optimized formulation exhibited nanosized vesicles (199 nm for FEB and 365 nm for ACE), high entrapment efficiency (> 80%), and stable zeta potential values. The ufasomal gel demonstrated sustained in vitro drug release over 24 h compared with plain drug gel, while ex vivo permeation studies indicated controlled diffusion across rat skin, suggesting formation of a drug reservoir within cutaneous layers. The drug release follows 1st order model for FEB and ACE. In vivo pharmacodynamic studies showed significant reductions in serum uric acid levels (p < 0.01) and paw edema volume (p < 0.001). These findings suggest that the FEB–ACE ufasomal transdermal gel offers a sustained delivery platform that may improve therapeutic outcomes and patient compliance in gout therapy. The novelty of this work lies in the dual-drug ufasomal transdermal system integrating urate-lowering and anti-inflammatory therapy in a single formulation, offering a potential alternative to conventional oral treatment for gout management with improved therapeutic convenience.
- 25 March 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (3)
Design and Development of Prolong-acting Intelligent Nano-depot (PaIND) for Improving Patient Adherence
Medication adherence is a major limitation in the current era. The purpose of the current research was to develop a Prolong-acting intelligent nano-depot (PaIND) for patients diagnosed with hypercholesterolemia, utilizing Rosuvastatin (RSV), to reduce the need for frequent medication administration. PaIND were formulated with poly(lactic-co-glycolic acid 75:25) (PLGA) as the biodegradable polymer, Dimethyl sulfoxide (DMSO) as the solvent, sesame oil as the oil, Span 80 and Tween 80 as the surfactant and co-surfactant, respectively. PaIND was developed systematically by application of quality by design (QbD). A risk assessment approach and Taguchi design were used to screen for significant materials (CMAs) and process attributes (CPPs). PaIND was optimized by applying central composite design (CCD). PaIND was designed and evaluated for prolonged controlled RSV release, gelling time, nano-sized particles, stability, sterility, and other parameters. The chosen excipients showed controlled delivery over a prolonged period, with no signs of burst release. Higher delta values and S/N ratios in the Taguchi design indicate a significant influence of the amount of PLGA, span 80, and tween 80 on the quality of PaIND. Quadratic effect was observed for each CMA on chosen CQAs in CCD. The optimum PaIND showed 86.99% RSV release in 30 days, a 173 nm size, and a 3.6 s gelling time-physical properties aligned with prolonged drug release. Lower PDI and viscosity, negative zeta potential, high transmittance and entrapment efficiency, improved stability and sterility, better use of PaIND. PaIND was successfully designed and developed, integrating recent regulatory compliance requirements. The newer system is highly patient-friendly and ready for commercial use following successful preclinical trials.
- 25 March 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (3)
Design and Development of Prolong-acting Intelligent Nano-depot (PaIND) for Improving Patient Adherence
Medication adherence is a major limitation in the current era. The purpose of the current research was to develop a Prolong-acting intelligent nano-depot (PaIND) for patients diagnosed with hypercholesterolemia, utilizing Rosuvastatin (RSV), to reduce the need for frequent medication administration. PaIND were formulated with poly(lactic-co-glycolic acid 75:25) (PLGA) as the biodegradable polymer, Dimethyl sulfoxide (DMSO) as the solvent, sesame oil as the oil, Span 80 and Tween 80 as the surfactant and co-surfactant, respectively. PaIND was developed systematically by application of quality by design (QbD). A risk assessment approach and Taguchi design were used to screen for significant materials (CMAs) and process attributes (CPPs). PaIND was optimized by applying central composite design (CCD). PaIND was designed and evaluated for prolonged controlled RSV release, gelling time, nano-sized particles, stability, sterility, and other parameters. The chosen excipients showed controlled delivery over a prolonged period, with no signs of burst release. Higher delta values and S/N ratios in the Taguchi design indicate a significant influence of the amount of PLGA, span 80, and tween 80 on the quality of PaIND. Quadratic effect was observed for each CMA on chosen CQAs in CCD. The optimum PaIND showed 86.99% RSV release in 30 days, a 173 nm size, and a 3.6 s gelling time-physical properties aligned with prolonged drug release. Lower PDI and viscosity, negative zeta potential, high transmittance and entrapment efficiency, improved stability and sterility, better use of PaIND. PaIND was successfully designed and developed, integrating recent regulatory compliance requirements. The newer system is highly patient-friendly and ready for commercial use following successful preclinical trials.
- 16 March 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (3) , 309
Exploring the Cardio-Protective Potential of Eclipta alba Leaves and Its Formulations in Cardiac Fibrosis-Induced Experimental Rats
- 16 March 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (3) , 309
Exploring the Cardio-Protective Potential of Eclipta alba Leaves and Its Formulations in Cardiac Fibrosis-Induced Experimental Rats
- 2 November 2025
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 29 (6) , 2508-2518
Simultaneous quantification of quercetin and rifampicin in bronchoalveolar lavage fluid by HPLC-UV technique and its application to a pharmacokinetic study of investigational dry powder formulation
A rapid and precise high-performance liquid chromatography with ultraviolet detection (HPLC-UV) method has been developed for the quantitative determination of Rifampicin and Quercetin, in bronchoalveolar lavage fluid. The validation process was conducted in compliance with the USFDA guidelines. Separation was achieved using a C18-Luna Phenomenex column (5 μm, 4.60 × 150 mm) with a mobile phase comprising 20 mM disodium hydrogen orthophosphate (pH 4.5) and methanol in a 35:65 %v/v ratio. The retention times for Quercetin and Rifampicin were 5.42 and 8.60 minutes, respectively. Optimal protein precipitation was achieved using 500 μl of acetonitrile and 500 μl of methanol, yielding an extraction recovery exceeding 80 % for both drugs from bronchoalveolar lavage fluid. The extraction method yielded clean samples, rendering the process both straightforward and cost-effective. The method exhibited a strong linear correlation (r > 0.9995) between the peak area ratio and the concentrations for Rifampicin (50– 5000 ng/ml) and Quercetin (40–4000 ng/ml). Pharmacokinetic analysis revealed that poly(lactic-co-glycolic acid) nanoparticles sustained higher drug concentrations in the lung tissue for an extended period of up to 24 hours. In conclusion, the developed HPLC method, utilizing simple UV detection, offers several advantages, including costeffectiveness, high recovery rates, a broad linear range, robust quantification capability, and short analysis times.
- 2 November 2025
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 29 (6) , 2508-2518
Simultaneous quantification of quercetin and rifampicin in bronchoalveolar lavage fluid by HPLC-UV technique and its application to a pharmacokinetic study of investigational dry powder formulation
A rapid and precise high-performance liquid chromatography with ultraviolet detection (HPLC-UV) method has been developed for the quantitative determination of Rifampicin and Quercetin, in bronchoalveolar lavage fluid. The validation process was conducted in compliance with the USFDA guidelines. Separation was achieved using a C18-Luna Phenomenex column (5 μm, 4.60 × 150 mm) with a mobile phase comprising 20 mM disodium hydrogen orthophosphate (pH 4.5) and methanol in a 35:65 %v/v ratio. The retention times for Quercetin and Rifampicin were 5.42 and 8.60 minutes, respectively. Optimal protein precipitation was achieved using 500 μl of acetonitrile and 500 μl of methanol, yielding an extraction recovery exceeding 80 % for both drugs from bronchoalveolar lavage fluid. The extraction method yielded clean samples, rendering the process both straightforward and cost-effective. The method exhibited a strong linear correlation (r > 0.9995) between the peak area ratio and the concentrations for Rifampicin (50– 5000 ng/ml) and Quercetin (40–4000 ng/ml). Pharmacokinetic analysis revealed that poly(lactic-co-glycolic acid) nanoparticles sustained higher drug concentrations in the lung tissue for an extended period of up to 24 hours. In conclusion, the developed HPLC method, utilizing simple UV detection, offers several advantages, including costeffectiveness, high recovery rates, a broad linear range, robust quantification capability, and short analysis times.
- 10 October 2025
- Published by Springer Nature in Biomedical Materials & Devices
- p. 1-21
3D Printlet-Nano Intelligent Lipoidal System (3DP-NIL): Designing, Amalgamation, and Optimization
- 10 October 2025
- Published by Springer Nature in Biomedical Materials & Devices
- p. 1-21
3D Printlet-Nano Intelligent Lipoidal System (3DP-NIL): Designing, Amalgamation, and Optimization
- 10 October 2025
- Published by Springer Nature in Accreditation and Quality Assurance
- Vol. 30 (6) , 773-785
An eco-friendly HPTLC approach for the estimation of febuxostat and aceclofenac in ufasomal gel
- 10 October 2025
- Published by Springer Nature in Accreditation and Quality Assurance
- Vol. 30 (6) , 773-785
An eco-friendly HPTLC approach for the estimation of febuxostat and aceclofenac in ufasomal gel